Send to:

Choose Destination
See comment in PubMed Commons below
Crit Rev Oncol Hematol. 2012 Jul;83(1):130-44. doi: 10.1016/j.critrevonc.2011.09.004. Epub 2012 Jan 24.

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.

Author information

  • 1Abramson Cancer Center, Hematology/Oncology Division, University of Pennsylvania, Philadelphia, PA, USA.


Non-small cell lung cancer is the leading cause of cancer death in the United States. Efforts to improve outcomes have led to a greater understanding of the predictive and prognostic value of histologic and molecular characteristics of individual tumors. In standard practice, biopsy specimens are examined first on a histologic level, then on a molecular level with the recognition that both histologic subtype and gene expression profile can guide treatment decisions and have a profound effect on clinical outcomes. Epidermal growth factor activation mutations were among the first biomarkers shown to have therapeutic implications, and levels of gene expression for an array of other biomarkers are being evaluated in clinical trials. Ongoing studies underscore the need to implement molecular and histologic screening as part of routine clinical practice. To achieve an integration of clinical, histologic, and molecular parameters when making treatment decisions, collaboration between oncologists and pathologists is essential.

Copyright © 2012. Published by Elsevier Ireland Ltd.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk